Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pushing estrogen receptor around in breast cancer.
Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C. Lim E, et al. Among authors: portman n. Endocr Relat Cancer. 2016 Dec;23(12):T227-T241. doi: 10.1530/ERC-16-0427. Epub 2016 Oct 11. Endocr Relat Cancer. 2016. PMID: 27729416 Review.
Non-canonical AR activity facilitates endocrine resistance in breast cancer.
Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E. Chia K, et al. Among authors: portman n. Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333. Endocr Relat Cancer. 2019. PMID: 30557851
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR. Kennedy SP, et al. Among authors: portman n. Breast Cancer Res. 2019 Mar 21;21(1):43. doi: 10.1186/s13058-019-1127-y. Breast Cancer Res. 2019. PMID: 30898150 Free PMC article.
Targeting CDK2 in cancer: challenges and opportunities for therapy.
Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, Wang S. Tadesse S, et al. Among authors: portman n. Drug Discov Today. 2020 Feb;25(2):406-413. doi: 10.1016/j.drudis.2019.12.001. Epub 2019 Dec 10. Drug Discov Today. 2020. PMID: 31839441 Review.
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou S, Llop-Guevara A, Phan Z, Yong A, Wilkinson A, Sergio CM, Ferraro D, Etemadmoghadam D, Bowtell DD; kConFab Investigators; Serra V, Waring P, Lim E, Caldon CE. Aziz D, et al. Among authors: portman n. NPJ Breast Cancer. 2021 Aug 31;7(1):111. doi: 10.1038/s41523-021-00312-x. NPJ Breast Cancer. 2021. PMID: 34465787 Free PMC article.
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL, Ehmsen S, Terp MG, Portman N, Tuttolomondo M, Gammelgaard OL, Hundebøl MF, Kaminska K, Johansen LE, Bak M, Honeth G, Bosch A, Lim E, Ditzel HJ. Alves CL, et al. Among authors: portman n. Nat Commun. 2021 Sep 16;12(1):5588. doi: 10.1038/s41467-021-25901-z. Nat Commun. 2021. PMID: 34531405 Free PMC article. No abstract available.
35 results